FindTrial
Sign In

Comparison of the efficacy and safety of Hetrombopag and other thrombopoietin receptor agonists in the treatment of primary Immune thrombocytopenia

Comparison of the efficacy and safety of Hetrombopag and other thrombopoietin receptor agonists in the treatment of primary Immune thrombocytopenia: a multicenter retrospective cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096457
Enrollment
Unknown
Registered
2025-01-24
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary immune thrombocytopenia

Interventions

Hetrombopag group:None
Control group:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Diagnosis of primary ITP; 2) Age>=18 years.

Exclusion criteria

Exclusion criteria: 1) Secondary ITP; 2) Concurrent pregnancy; 3) Patients with other hematologic disorders (e.g., abnormal platelet aggregation, Evans syndrome, and non-immune or hereditary thrombocytopenia).

Design outcomes

Primary

MeasureTime frame
Platelet count;—

Secondary

MeasureTime frame
Postoperative complications;—

Countries

China

Contacts

Public ContactTing Niu

West China Hospital,Sichuan University

niuting@wchscu.cn+86 189 8060 1242

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026